Atara Biotherapeutics Financial Statements (ATRA)
|
|
|
|
Report date
|
|
|
27.02.2020 |
01.03.2021 |
28.02.2022 |
08.02.2023 |
28.03.2024 |
|
12.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
0.000 |
0.000 |
20.3 |
63.6 |
8.57 |
|
100.4 |
|
Operating Income, bln rub |
|
|
-295.7 |
-309.1 |
-340.5 |
-280.5 |
-276.0 |
|
-119.8 |
|
EBITDA, bln rub |
? |
|
-282.9 |
-296.7 |
-331.1 |
-213.7 |
-266.0 |
|
-123.2 |
|
Net profit, bln rub |
? |
|
-2 910 |
-3 066 |
-3 401 |
-2 283 |
-276.1 |
|
-963.0 |
|
|
OCF, bln rub |
? |
|
-235.6 |
-180.8 |
-220.5 |
-270.4 |
-193.0 |
|
-94.7 |
|
CAPEX, bln rub |
? |
|
5.73 |
4.51 |
10.6 |
4.19 |
1.22 |
|
0.200 |
|
FCF, bln rub |
? |
|
-241.4 |
-185.3 |
-231.1 |
-274.6 |
-194.2 |
|
-94.9 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
295.7 |
309.1 |
360.8 |
344.1 |
275.7 |
|
202.8 |
|
Cost of production, bln rub |
|
|
8.11 |
9.87 |
11.4 |
14.6 |
8.89 |
|
17.4 |
|
R&D, bln rub |
|
|
216.1 |
244.7 |
282.0 |
272.5 |
224.8 |
|
163.3 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
0.000 |
1.99 |
5.29 |
|
4.77 |
|
|
Assets, bln rub |
|
|
342.9 |
588.1 |
468.1 |
376.4 |
165.5 |
|
142.7 |
|
Net Assets, bln rub |
? |
|
290.8 |
462.3 |
279.6 |
126.6 |
-99.2 |
|
-90.5 |
|
Debt, bln rub |
|
|
14.1 |
13.0 |
25.5 |
71.7 |
57.9 |
|
35.2 |
|
Cash, bln rub |
|
|
259.1 |
500.7 |
371.1 |
242.8 |
51.7 |
|
67.2 |
|
Net debt, bln rub |
|
|
-245.0 |
-487.6 |
-345.6 |
-171.1 |
6.15 |
|
-31.9 |
|
|
Ordinary share price, rub |
|
|
411.8 |
490.8 |
394.0 |
82.0 |
12.8 |
|
1.20 |
|
Number of ordinary shares, mln |
|
|
2.05 |
2.96 |
3.75 |
4.08 |
4.24 |
|
7.47 |
|
|
Market cap, bln rub |
|
|
845 |
1 452 |
1 476 |
335 |
54 |
|
9 |
|
EV, bln rub |
? |
|
600 |
964 |
1 131 |
163 |
60 |
|
-23 |
|
Book value, bln rub |
|
|
291 |
462 |
280 |
127 |
-99 |
|
-91 |
|
|
EPS, rub |
? |
|
-1 418 |
-1 036 |
-907.8 |
-559.6 |
-65.2 |
|
-129.0 |
|
FCF/share, rub |
|
|
-117.6 |
-62.6 |
-61.7 |
-67.3 |
-45.8 |
|
-12.7 |
|
BV/share, rub |
|
|
141.7 |
156.3 |
74.6 |
31.0 |
-23.4 |
|
-12.1 |
|
|
EBITDA margin, % |
? |
|
|
|
-1 628% |
-336.2% |
-3 103% |
|
-122.7% |
|
Net margin, % |
? |
|
|
|
-16 723% |
-3 591% |
-3 221% |
|
-958.8% |
|
FCF yield, % |
? |
|
-28.6% |
-12.8% |
-15.7% |
-82.1% |
-357.6% |
|
-1 059% |
|
ROE, % |
? |
|
-1 001% |
-663.2% |
-1 216% |
-1 803% |
278.3% |
|
1 064% |
|
ROA, % |
? |
|
-848.5% |
-521.4% |
-726.6% |
-606.5% |
-166.8% |
|
-674.8% |
|
|
P/E |
? |
|
-0.29 |
-0.47 |
-0.43 |
-0.15 |
-0.20 |
|
-0.01 |
|
P/FCF |
|
|
-3.50 |
-7.84 |
-6.39 |
-1.22 |
-0.28 |
|
-0.09 |
|
P/S |
? |
|
|
|
72.6 |
5.26 |
6.34 |
|
0.09 |
|
P/BV |
? |
|
2.91 |
3.14 |
5.28 |
2.64 |
-0.55 |
|
-0.10 |
|
EV/EBITDA |
? |
|
-2.12 |
-3.25 |
-3.41 |
-0.76 |
-0.23 |
|
0.19 |
|
Debt/EBITDA |
|
|
0.87 |
1.64 |
1.04 |
0.80 |
-0.02 |
|
0.26 |
|
|
R&D/CAPEX, % |
|
|
3 769% |
5 421% |
2 665% |
6 500% |
18 380% |
|
81 675% |
|
|
CAPEX/Revenue, % |
|
|
|
|
52.0% |
6.60% |
14.3% |
|
0.20% |
|
| Atara Biotherapeutics shareholders |
